This process culminates in the cross-presentation of antigenic peptides on major histocompatibility complex class I (MHC I) molecules to CD8+ T cells of the adaptive immune system [29], a major driving force of effective control of tumors and long-term anti-cancer immunity. Here, CD8A is linked to cancer.